Learn Before
Results: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- The placebo experienced no antibody increase from the baseline
- The low dose had a 97% seroconversion of specific antibodies on day 28 and a significant antibody response
- 96 of 129 participants who received the low dose reported solicited ADRs and 1 reported a severe ADR
- the high dose had a 96% seroconversion of specific antibodies on day 28 and a significant antibody response
- 183 of 253 participants who received the high dose reported solicited ADRs and 24 reported a severe ADR
- T cell responses were negative in 99% of participants
- The vaccines induced significant specific IFNγ-ELISpot responses
- no serious ADRs were documented
- The vaccine candidate was found to be safe at low doses and capable of a significant immune response in the majority of subjects after a single injection
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Methods: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Results: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Discussion: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial